Tilray, Inc. Series 2 Stock News

As cannabis markets shift this week, Canadian cannabis stocks are once again gaining investor attention. At the same time, the U.S. industry continues to grow rapidly. In 2024, legal cannabis sales in the U.S. reached nearly $39 billion. Projections suggest that the number could climb past $44 billion in 2025. Growth is expected to continue at a strong pace through the decade. Despite this mome...

Tilray Brands stock price has triggered a short squeeze this month as it surged to a high of $0.6570, its highest point since April 1, and 90% from its lowest point this year. Its market capitalization has jumped to over $680 million.

The S&P 500 index has been hitting record highs and may be running out of room to rise a whole lot more. For investors, now may be an opportune time to pay attention to stocks which may be poised for greater gains and which haven't been doing particularly well.

Tilray Brands Inc. NASDAQ: TLRY, once a leading light in the legal cannabis industry with shares trading as high as nearly $150, has seen its stock price almost entirely collapse in recent years. A multitude of factors may be to blame—the lack of federal legalization of recreational cannabis, regulatory inconsistencies, problems matching supply and demand, and more have all devastated the indus...

NEW YORK and LEAMINGTON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the fourth quarter and full fiscal year ended May 31, 2025,...

Tilray Brands is a high-risk, high-reward opportunity after a 99%+ decline over seven years, now trading at deep value levels with minimal bankruptcy risk. The company is nearing profitability, with projected positive cash flow in 2025-26, marking a significant turnaround from years of losses. Potential U.S. regulatory changes under President Trump could dramatically boost industry sentiment an...

Canadian LPs offer compelling risk/reward versus U.S. cannabis stocks, with stronger balance sheets, tangible book value, and global opportunities due to federal legality. Despite recent rallies, Canadian LPs remain cheap on enterprise value to EBITDA, especially Village Farms, Organigram, and Tilray Brands, which I hold in my model portfolio. U.S. MSOs face significant risks from 280E tax liab...